We? Do pray tell, which investment house is your family affiliated with? What options arena does your home team play in... weeklies, monthlies? And what is the option strategy of choice for your gang?
I can't wait to see the analyst updates from Wedbush and CS.
@Date Firm Action Rating Price Target Actions
4/6/2016 Cowen and Company Lower Price Target Market Perform $25.00 - $23.00
4/6/2016 Canaccord Genuity Lower Price Target Hold $26.00 - $24.00
3/28/2016 Wedbush Lower Price Target Outperform $77.00 - $73.00
3/28/2016 Credit Suisse Lower Price Target Neutral $60.00 - $50.00
CREE defies any and all logic. It's an options playhouse for the big boys to take poor saps 'money. Remember, the house always wins. And with weekly options traded on CREE for many years now, the house's pockets are stuffed to the brim with lots of cold hard electronic cash.
At CREE that does not matter. Neither does blowout earnings results at competitor AYI today. Funny how no analyst rates CREE a sell despite over a year of dismal results.At CREE hope springs eternal. At least that's what the big boys want you to believe. That way they can keep ringing up the options cash register week after week. month after month, to the general detriment of the trading crowd attracted to this company, like flies to a turd.
Did you see the price level the trade crossed at vs bid/ask? At the current bid/ask, stock price, and day range, it looks like that trade happened closer to the bid than the ask ie. someone selling calls (covered?) which is not really bullish.
This could explain why BXLT was hit so hard.
@Also possible that the slump in Allergan shares is forcing arb funds to close out other risk-arb positions as result of the expected loss in the AGN/PFE bet.
Yeah, like no one here ever saw any of your millions of daily reminders. Get a life.
Street fight - Round 7
The chairman of the transportation committee delivered what appears to be a knockout punch to CP. Hunter HH (HardHead) Harrison hit the mat hard and is down for the count. One... Two.. .Three...Four...Five...and no sign of him getting back up yet.
@WASHINGTON/CHICAGO — The chairman of the U.S. House Transportation and Infrastructure Committee announced his opposition on Tuesday to Canadian Pacific’s proposed railroad merger with Norfolk Southern Corp, dealing a fresh blow to the prospect of a deal. Shuster noted that Canadian Pacific had actively pursued a merger in the United States since 2014. An earlier bid was rejected by CSX Corp. “A strong, healthy and well-functioning freight rail system is critical to the movement of goods in this country,” he said in his statement. “However, CP’s pursuit of a merger over the last two years has done nothing but create uncertainty in the rail industry, and there continues to be no clear path forward for such an arrangement.
If there's any tax-related issue that could derail this deal, I think it's not new Treasury rules, but rather a change in opinions of lawyers advising the companies on the purported IRS tax-free status of the spinoff by BAX of BXLT
@Here’s how the arrangements among the three companies break down. Because post-spinoff deals could result in a tax bill for Baxter, it’s indemnified by Baxalta if it does a deal that triggers a tax on the spinoff. Shire will guarantee that indemnity once the purchase of Baxalta closes. Baxter, in turn, has a veto right over a takeover of Baxalta. All of that is typical for a spin-off. In a letter agreement signed on Monday, Baxter agreed to waive its veto right as long as Baxter receives a favorable tax opinion from its tax adviser and Shire receives a such an opinion from its tax lawyer. No mention is made of a tax opinion from Baxalta’s lawyer, although it’s entitled to a copy of the opinion delivered to Shire. Baxter and Shire also received similar letters prior to the signing, but the requirement for redelivery of those opinions at closing allows them to take a second look at the issue if their advisers to change their tune.
Exactly. I don't see how any Treasury move would affect the SHPG-BXLT deal as, unlike in the case of PFE-AGN, it's not an inversion deal. If there was really concern that the deal was in jeopardy now because of these latest actions by Treasury, then SHPG should be moving up, not down. It's likely just general uncertainty in view of the fact that SHPG is based in the UK. Let's see what analysts have to say in the next days ahead.
SHPG's presentation on the merger sums up the debt situation (I tried posting part of it but YHOO blocks it). Anyway, although leverage will go up, it is expected to be between 2-3X in fairly short order. Sure that's high relative to several large pharma companies I took a look at, but it seems quite manageable.. ABBV for example is running at ~1.5X.
With annual FCF forecast to be 6B (versus ~2B in recent years), the 18B debt related to the acquisition could potentially be paid off in as little as three years. The company plans to maintain an investment grade debt rating which will keep a cap on interest costs of debt going forward. So overall, I see no major concerns on the debt front.
GS doesn't feel the love for NILSY any more. Downgraded from Buy to Neutral. I say screw GS.
Sounds like someone is fed up of their job. Life's short... go find a better company to work for or maybe start a new career.
Another step forward by SHPG to maintain its dominance in the ADHD market space.
@ Lexington, Mass. - April 4, 2016- Shire plc today announces positive topline results from a four-week Phase 3, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, safety and efficacy study, SHP465-305, in children and adolescents aged 6-17 years with Attention-Deficit/Hyperactivity Disorder (ADHD). SHP465 (triple-bead mixed amphetamine salts - MAS) is an investigational oral stimulant medication being evaluated in the U.S. as a potential treatment for ADHD, a therapeutic area with significant need for additional treatment options. The primary efficacy analysis of study 305 demonstrated that SHP465, administered as a daily morning dose, was superior to placebo on the change from baseline in ADHD-RS-IV (ADHD rating scale) total score, with a Least Squares (LS) mean difference from placebo at Week 4 of -9.9 (95% CI: -13.0 to -6.8, p
@ Overall Robust SHP465 Clinical Development Program to Support Class 2 Resubmission Including study 305 and previous studies, Shire now has a robust database of 15 clinical studies evaluating SHP465 in more than 1,100 subjects. Once the pharmacokinetic study and an additional safety and efficacy Phase 3 trial in adults currently under way are complete later this year, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD. SHP465 remains on track for potential U.S. launch in the second half of 2017. Protection for Shire's ADHD
@Franchise Extends to 2029 There are patents supporting Shire's overall ADHD franchise in the U.S. that extend to 2029. With a launch planned for the second half of 2017, Shire expects that SHP465, following potential FDA approval, will have three years of Hatch-Waxman exclusivity and at least three patents listed in the FDA Orange Book expiring as late as May 2029.
QCOM's Mirasol MEMS technology is fundamentally different from the Sharp-QCOM PIxtronix MEMS design. From what I've read, the former is based on optical interferometry principles, while the latter acts as simple light shutter. These are technically two very different approaches.. Just because Mirasol failed to achieve commercial success does not imply the same fate awaits the Pixtronix design.
Mirasol ----- Meeting new mobile consumer demands requires new ways of thinking, like creating a color screen that uses reflected light and something called interferometric modulation (IMOD). Mirasol displays are extremely efficient because they don’t emit light—they reflect it. Microscopic mirrors in each pixel change the size of an air gap inside the display. Depending on the size of the gap, white light is reflected back as red, green, or blue. And it’s inside that air pocket where the magic happens. That’s where the light is harnessed and the interference occurs, creating either a rainbow effect, or a single color.
Pixtronix ----- The screen technology from Pixtronix, a display company in Andover, Mass., is called PerfectLight. LCD, the current screen technology, is inefficient because it loses much of its optical energy as light passes through polarizers, filters and crystals. That optical loss doesn’t occur in PerfectLight because the liquid crystals, polarizers and color filters of LCDs are eliminated, Mr. Halfman said. Instead, the image is created with thousands of digitally controlled, microelectro-mechanical system, or MEMS, shutters that open and close over each pixel opening, allowing light from the red, green and blue LEDs to pass through.